Fluorescence in situ hybridization

Sysmex America Becomes Exclusive Distributor of vermicon VIT® System in Canada, Latin America and Americas

Retrieved on: 
Thursday, December 14, 2023
FISH, Microbiology, Fluorescence in situ hybridization, VIT, Drinking water, Documentation, Bacteria, Cell, Fluorescence

CHICAGO, Dec. 14, 2023 /PRNewswire/ -- Sysmex America, Inc. , a leading diagnostic solutions company, has been named the exclusive distributor of vermicon identification technology (VIT®) System in Canada, Latin America and all the Americas.

Key Points: 
  • CHICAGO, Dec. 14, 2023 /PRNewswire/ -- Sysmex America, Inc. , a leading diagnostic solutions company, has been named the exclusive distributor of vermicon identification technology (VIT®) System in Canada, Latin America and all the Americas.
  • The VIT System is an all-in-one test kit for the wastewater, beverage, mineral water and food industries that delivers unparalleled precision in quantifying microorganisms.
  • The complete kit includes the VIT® microscope, VIT® test kits, VIT® Cam, VIT® Vision software and all consumables.
  • "Our customers will benefit from the robust VIT System that provides much needed convenience, speed, specificity and reliability, especially for wastewater testing," said Andy Hay, CEO of Sysmex America.

Global Molecular Cytogenetics Market Research Report 2023: Rising Adoption of Array Based CGH to Spur Overall Demand - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 26, 2023
Research, Science, Age, Developed country, Growth, Genetic, Personalized medicine, Prevalence, Development, Incidence, Software, Genetic disorder, Fluorescence in situ hybridization, Fluorescence, Comparative genomic hybridization, Real, COVID-19, CGH, Molecular Cytogenetics, Molecular biology, Abbott Laboratories, Thermo Fisher Scientific, Total, Table, Cornerstone, Consumables, Fine chemical, Retail, Agriculture, Tourism, Video game, Karyotype, Immunohistochemistry, Revenue, Cancer, Instrument

The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Cytogenetics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • This market encompasses various facets, including Molecular Cytogenetics itself, Consumables, Instruments, Software & Services, as well as techniques like CGH (Comparative Genomic Hybridization), FISH (Fluorescence In Situ Hybridization), Immunohistochemistry, Karyotyping, and other methods.
  • The U.S. market, with an estimated worth of US$794.6 million in 2022, holds a prominent position within this market.
  • This report provides an extensive analysis of the global Molecular Cytogenetics market, furnishing insights into annual revenues, historical patterns, and future forecasts spanning from 2014 to 2030.

Lunit to Showcase 9 AI-based Research Results at ESMO 2023

Retrieved on: 
Tuesday, October 10, 2023
Congress, H&E, Fluorescence, Lung cancer, Abstract, Breast cancer, Breast, AI, Therapy, Safety, TIL, Patient, Spatial analysis, European Society for Medical Oncology, ESMO, Oncology, Collection, Leiomyosarcoma, Fluorescence in situ hybridization, Cholangiocarcinoma, Pathology, ICI, Colon cancer staging, Affirmative action, Prognosis, HER2, Research, DNA mismatch repair, Medical device, Medical imaging, Vaccine

SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 9 studies featuring its AI pathology research at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, scheduled to be held in Madrid, Spain, from October 20 to October 24, 2023.

Key Points: 
  • The highlighted abstracts for ESMO 2023 include:
    Lunit investigates AI's potential to predict multiple druggable mutations in non-small cell lung cancer from H&E stained images, paving the way for more efficient clinical workflows and treatment decisions.
  • In another study utilizing Lunit SCOPE HER2, Lunit assesses HER2 expression and TIL (Tumor-infiltrating lymphocyte) density in biliary tract cancer, providing valuable insights into the tumor microenvironment's role in treatment strategies.
  • "These groundbreaking abstracts showcase the power of the Lunit SCOPE suite in unraveling complex insights across various cancer types, from distinguishing tumor subtypes to predicting treatment responses," said Brandon Suh, CEO of Lunit.
  • For inquiries or to schedule a meeting with the Lunit team, please contact [email protected] .

Lung Cancer Genomic Testing Markets, 2031 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 21, 2022
Health, Oncology, EGFR, CAGR, ROS, Cobas, FDA, Drug development, COVID-19, ALK, Polymerase chain reaction, FISH, LabCorp, Qiagen, IVD, Precision medicine, Efficiency, LDT, MET, Polymerase, Adoption, Research, Hospital, BIS, Growth, Takeda, Real-time polymerase chain reaction, Cdx, DNA sequencing, NGS, Investment, Roche, Quest Diagnostics, Thermo Fisher Scientific, Amgen, Partnership, Fluorescence in situ hybridization, Region, Lung cancer, Patient, KRAS, In situ hybridization, Diagnosis, Awareness, PCR, Organization, Large-cell lung carcinoma, Antibiotics, Medical imaging, Technology, Fluorescence, NSCLC

The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.

Key Points: 
  • The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics.
  • Various companies are increasing investments in research and development to facilitate the development of lung cancer genomic testing, which is expected to further increase the adoption of lung cancer genomic tests.
  • Increasing recommendations by the international oncology societies for the use of genomic testing for lung cancer diagnosis provides major opportunities in the global lung cancer genomic testing market.
  • Since the lung cancer genomic testing is categorized under the elective procedure, the impact of the COVID-19 pandemic on the lung cancer genomic testing was negative.

Global In-situ Hybridization Market Research Report 2022: Market to Reach $1.1 Billion by 2026 - Future Prospects Remain Favorable - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 22, 2022
Pharmaceutical, Genetics, Health, Clinical Trials, Cell, ISH, CAGR, In situ hybridization, Population, DNA, Fluorescence, Lists of diseases, Growth, FISH, Research, Fluorescence in situ hybridization, Incidence, Cancer, CGH, Laboratory, Chromogenic in situ hybridization, Hybridisation, Awareness, Oil, Pet, Pharmaceutical industry

In-situ hybridization helps in the precise localization of a specific nucleic acid segment in a histologic specimen.

Key Points: 
  • In-situ hybridization helps in the precise localization of a specific nucleic acid segment in a histologic specimen.
  • This segment currently accounts for a 28.6% share of the global In Situ Hybridization (ISH) market.
  • The market is poised to post healthy growth over the coming years, driven by various favorable factors steering market expansion.
  • Rise in incidence of cancer and the subsequent demand for personalized medicine, is likely to enhance market prospects in a major way.

Bionano’s Optical Genome Mapping Reveals New Insights and Prognostic Capabilities Compared to Traditional Cytogenetics Techniques in Several Leukemia Clinical Research Studies Presented at the ECA

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Biology, Cytogenetics, Molecular biology, Laboratory techniques, Anatomical pathology, Fluorescence in situ hybridization, Pathology, Karyotype, Ogm, Polymerase chain reaction, Genome

SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA).

Key Points: 
  • SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA).
  • In this study, 34 pediatric leukemias (26 ALL and 8 AML) were analyzed by OGM relative to traditional cytogenetics techniques (karyotyping, FISH, and PCR).
  • This study is the basis of validation and accreditation of an assay to be used onsite in their lab.
  • In 45% of cases, OGM provided additional information, orthogonally confirmed, demonstrating an improvement in diagnostic potential relative to traditional cytogenetics techniques.

Bio-Techne Announces Commercial Release of Novel DNAscope™ in situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations

Retrieved on: 
Tuesday, April 27, 2021
Branches of biology, Natural sciences, Biology, Laboratory techniques, Molecular biology, Assay, Fluorescence in situ hybridization, Fluorescence

b'MINNEAPOLIS, April 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope technology with release of new DNAscope Assays.

Key Points: 
  • b'MINNEAPOLIS, April 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope technology with release of new DNAscope Assays.
  • DNAscope delivers benefits over current commercial FISH techniques that fall short on morphological detail due to the use of fluorescent nuclear staining and rely on high-resolution microscopes to visualize gene rearrangement and copy number variation signals.
  • "These new assays provide simple workflows, easy data interpretation and enable faster decision making in critical spatial applications within the DNA ISH market.
  • "\nThe DNAscope Assay kits from Bio-Techne are intended for Research Use Only.\n'

Insights on the Cytogenetics Global Market to 2030 - Profiles of 70 Relevant Companies Along with Their 80 Collaborations

Retrieved on: 
Monday, April 26, 2021
Branches of biology, Biology, Laboratory techniques, Molecular biology, Cytogenetics, Genetics, Molecular Cytogenetics, Comparative genomic hybridization, Fluorescence in situ hybridization, Nucleic acid hybridization, In situ hybridization, Bioinformatics

Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879.

Key Points: 
  • Historical landmarks in the evolution of cytogenetics are reviewed since the first images of chromosomes were made in 1879.
  • The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH.
  • Molecular cytogenetics includes the applicationS of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection.
  • Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies.\nFISH remains the single most important technology in cytogenetics.

Global Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis to 2027 by Disease Type; By Technology; By Specialty; By End-Use; By Regions - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 25, 2021
Health, Genetics, Branches of biology, Biology, Molecular biology, Biotechnology, Medical genetics, Laboratory techniques, Medical tests, Polymerase chain reaction, DNA sequencing, Genetic testing, Fluorescence in situ hybridization, Elective genetic and genomic testing

The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region.

Key Points: 
  • The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region.
  • Based on technology, the rare disease genetic testing industry is further bifurcated into next-generation sequencing, array technology, PCR-based testing, FISH, sanger sequencing, and karyotyping.
  • Based on specialty, the rare disease genetic testing industry is further bifurcated into molecular, chromosomal, and biochemical genomic tests.
  • Based on end-use, the rare disease genomic testing industry is further bifurcated into research laboratories & CROs, hospitals & clinics, and diagnostic laboratories.

Flagship Biosciences Announces Patent

Retrieved on: 
Wednesday, February 17, 2021
Branches of biology, Biology, Laboratory techniques, United States Patent and Trademark Office, United States trademark law, Fluorescence in situ hybridization, Pathology

WESTMINSTER, Colo., Feb. 17, 2021 /PRNewswire-PRWeb/ --Flagship Biosciences, the leader in data-centric pathology tissue analysis, today announced that the United States Patent and Trademark Office has issued Flagship a new patent, number 10,839,512 entitled "Method of dot detection within images of tissue samples."

Key Points: 
  • WESTMINSTER, Colo., Feb. 17, 2021 /PRNewswire-PRWeb/ --Flagship Biosciences, the leader in data-centric pathology tissue analysis, today announced that the United States Patent and Trademark Office has issued Flagship a new patent, number 10,839,512 entitled "Method of dot detection within images of tissue samples."
  • "We are pleased to announce this new patent for CISH and FISH dot detection," said Trevor Johnson, Flagship's CEO.
  • The Flagship patent is written to cover the use of the new dot detection method exclusively in images of tissue sections.
  • Founded in 2009 and headquartered in Westminster, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available.